ZA974828B - Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids. - Google Patents

Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.

Info

Publication number: ZA974828B
Authority: ZA; South Africa
Prior art keywords: nhe; normalization; medicament; inhibitors; exchanger
Prior art date: 1996-06-03

Application number

ZA9704828A

Other languages

English (en)

Inventor

Hans Jochen Lang

Hans-Willi Jansen

Jan-Robert Schwark

Heinz-Werner Kleemann

Oliver Jung

Hans-Ludwig Schaefer

Wolfgang Linz

Werner Kramer

Bernward Schoelkens

Eugen Falk

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-03

Filing date

1997-06-02

Publication date

1997-12-03

1997-03-26 Priority claimed from DE19712636A external-priority patent/DE19712636A1/de

1997-06-02 Application filed by Hoechst Ag filed Critical Hoechst Ag

1997-12-03 Publication of ZA974828B publication Critical patent/ZA974828B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA9704828A 1996-06-03 1997-06-02 Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids. ZA974828B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19622222A DE19622222A1 (de)	1996-06-03	1996-06-03	Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19712636A DE19712636A1 (de)	1997-03-26	1997-03-26	Verwendung von Inhibitoren des zellulären Na+/H+Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide

Publications (1)

Publication Number	Publication Date
ZA974828B true ZA974828B (en)	1997-12-03

Family

ID=26026256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9704828A ZA974828B (en)	1996-06-03	1997-06-02	Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.

Country Status (23)

Country	Link
EP (1)	EP0918515B1 (xx)
JP (1)	JP4527811B2 (xx)
KR (1)	KR100511711B1 (xx)
CN (1)	CN1221339A (xx)
AR (1)	AR007353A1 (xx)
AT (1)	ATE293965T1 (xx)
AU (1)	AU722166B2 (xx)
BR (1)	BR9709516A (xx)
CA (1)	CA2257299A1 (xx)
DE (2)	DE19622222A1 (xx)
DK (1)	DK0918515T3 (xx)
ES (1)	ES2241049T3 (xx)
IL (1)	IL126935A0 (xx)
NO (1)	NO985480L (xx)
NZ (1)	NZ333095A (xx)
PL (1)	PL189950B1 (xx)
PT (1)	PT918515E (xx)
RU (1)	RU2211032C2 (xx)
SI (1)	SI0918515T1 (xx)
SK (1)	SK165898A3 (xx)
TR (1)	TR199802505T2 (xx)
WO (1)	WO1997046226A2 (xx)
ZA (1)	ZA974828B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6160134A (en) *	1997-12-24	2000-12-12	Bristol-Myers Squibb Co.	Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6011059A (en) *	1997-12-24	2000-01-04	Bristol-Myers Squibb Company	Acyl guanidine sodium/proton exchange inhibitors and method
DE19859727A1 (de)	1998-12-23	2000-06-29	Aventis Pharma Gmbh	Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
EP1180029A4 (en)	1999-04-23	2002-10-02	Bristol Myers Squibb Co	BICYCLIC ACYL IHIBITORING SODIUM / PROTON EXCHANGER AND RELATED PROCEDURE.
DE19945302A1 (de) *	1999-09-22	2001-03-29	Merck Patent Gmbh	Biphenylderivate als NHE-3-Inhibitoren
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
US6984645B2 (en)	2001-11-16	2006-01-10	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2856062B1 (fr) *	2003-06-12	2005-11-11	Aventis Pharma Sa	Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US7230007B2 (en)	2003-06-12	2007-06-12	Sanofi-Aventis Deutschland Gmbh	Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
EP2617709B8 (en) *	2003-06-26	2022-12-21	Biotron Limited	Guanidine derivatives as antiviral agents
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076569A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en)	2005-01-12	2008-01-01	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (en)	2005-01-18	2006-07-27	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (en)	2005-02-10	2009-01-21	Bristol-Myers Squibb Company	Dihydroquinazolinones as 5ht modulators
US7572808B2 (en)	2005-06-17	2009-08-11	Bristol-Myers Squibb Company	Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es)	2005-10-26	2007-09-19	Bristol Myers Squibb Co	Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
KR20110135411A (ko)	2009-03-27	2011-12-16	브리스톨-마이어스 스큅 컴퍼니	Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
CN102844313B (zh)	2010-01-28	2016-10-05	哈佛大学校长及研究员协会	提高蛋白酶体活性的组合物和方法
US9556166B2 (en)	2011-05-12	2017-01-31	Proteostasis Therapeutics, Inc.	Proteostasis regulators
WO2014039411A1 (en)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014039412A1 (en)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014116228A1 (en)	2013-01-25	2014-07-31	President And Fellows Of Harvard College	Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en)	2013-11-12	2015-05-21	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
BR112021000139A2 (pt)	2018-07-19	2021-04-06	Astrazeneca Ab	Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5110817A (en) *	1988-10-21	1992-05-05	Beyer Jr Karl H	Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) *	1988-10-21	1990-04-24	Beyer Jr Karl H	Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
AU7316591A (en) *	1990-02-28	1991-09-18	Upjohn Company, The	Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
EP0600973A1 (en) *	1991-08-27	1994-06-15	The Upjohn Company	A method for treatment of metabolic disorders and metabolism
ES2092729T3 (es) *	1992-07-01	1996-12-01	Hoechst Ag	Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
EP0612723B1 (de) *	1993-02-20	1997-08-27	Hoechst Aktiengesellschaft	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
DE4318658A1 (de) *	1993-06-04	1994-12-08	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) *	1993-07-31	1995-02-02	Hoechst Ag	Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU1882395A (en) *	1994-02-23	1995-09-11	Cambridge Neuroscience, Inc.	Blockers of ion channels and methods of use thereof
IL114670A0 (en) *	1994-08-05	1995-11-27	Fujisawa Pharmaceutical Co	Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

1996
- 1996-06-03 DE DE19622222A patent/DE19622222A1/de not_active Withdrawn
1997
- 1997-05-20 DE DE59712287T patent/DE59712287D1/de not_active Expired - Lifetime
- 1997-05-20 EP EP97923937A patent/EP0918515B1/de not_active Expired - Lifetime
- 1997-05-20 TR TR1998/02505T patent/TR199802505T2/xx unknown
- 1997-05-20 PL PL97330412A patent/PL189950B1/pl not_active IP Right Cessation
- 1997-05-20 AT AT97923937T patent/ATE293965T1/de not_active IP Right Cessation
- 1997-05-20 NZ NZ333095A patent/NZ333095A/xx unknown
- 1997-05-20 JP JP50014498A patent/JP4527811B2/ja not_active Expired - Fee Related
- 1997-05-20 CA CA002257299A patent/CA2257299A1/en not_active Abandoned
- 1997-05-20 AU AU29576/97A patent/AU722166B2/en not_active Ceased
- 1997-05-20 RU RU99100084/14A patent/RU2211032C2/ru not_active IP Right Cessation
- 1997-05-20 ES ES97923937T patent/ES2241049T3/es not_active Expired - Lifetime
- 1997-05-20 PT PT97923937T patent/PT918515E/pt unknown
- 1997-05-20 CN CN97195194A patent/CN1221339A/zh active Pending
- 1997-05-20 DK DK97923937T patent/DK0918515T3/da active
- 1997-05-20 WO PCT/EP1997/002548 patent/WO1997046226A2/de not_active Ceased
- 1997-05-20 IL IL12693597A patent/IL126935A0/xx not_active IP Right Cessation
- 1997-05-20 SI SI9730705T patent/SI0918515T1/sl unknown
- 1997-05-20 BR BR9709516A patent/BR9709516A/pt not_active Application Discontinuation
- 1997-05-20 KR KR10-1998-0709811A patent/KR100511711B1/ko not_active Expired - Fee Related
- 1997-05-20 SK SK1658-98A patent/SK165898A3/sk unknown
- 1997-05-30 AR ARP970102344A patent/AR007353A1/es unknown
- 1997-06-02 ZA ZA9704828A patent/ZA974828B/xx unknown
1998
- 1998-11-24 NO NO985480A patent/NO985480L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL126935A0 (en)	1999-09-22
TR199802505T2 (xx)	1999-04-21
KR100511711B1 (ko)	2005-12-26
WO1997046226A3 (de)	1998-03-05
SI0918515T1 (sl)	2005-12-31
SK165898A3 (en)	1999-05-07
DE19622222A1 (de)	1997-12-04
AU2957697A (en)	1998-01-05
KR20000016240A (ko)	2000-03-25
PL330412A1 (en)	1999-05-10
CN1221339A (zh)	1999-06-30
AU722166B2 (en)	2000-07-20
NO985480L (no)	1999-01-28
NZ333095A (en)	2000-08-25
BR9709516A (pt)	1999-08-10
WO1997046226A2 (de)	1997-12-11
DK0918515T3 (da)	2005-08-15
EP0918515B1 (de)	2005-04-27
AR007353A1 (es)	1999-10-27
DE59712287D1 (de)	2005-06-02
RU2211032C2 (ru)	2003-08-27
EP0918515A2 (de)	1999-06-02
JP2000506906A (ja)	2000-06-06
CA2257299A1 (en)	1997-12-11
JP4527811B2 (ja)	2010-08-18
ES2241049T3 (es)	2005-10-16
PL189950B1 (pl)	2005-10-31
PT918515E (pt)	2005-06-30
NO985480D0 (no)	1998-11-24
ATE293965T1 (de)	2005-05-15

Publication	Publication Date	Title
ZA974828B (en)	1997-12-03	Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.
AU5706499A (en)	2000-04-03	Planar ortho-mode transducer
ZA963130B (en)	1997-10-20	Arylsulfonyl hydroxamic acid derivatives.
AU9449398A (en)	1999-05-03	Use of csaidtm compounds for the management of uterine contractions
GB9814339D0 (en)	1998-09-02	Universal database adapters
AU4124996A (en)	1996-06-19	Pressure exchanger
AU2584495A (en)	1995-11-29	Immunoassay for homocysteine
AU1572895A (en)	1995-08-29	Nickel shell for molds
GB9411598D0 (en)	1994-08-03	Hydroxamic acid derivatives
IL140387A0 (en)	2002-02-10	Remedies for hypercalcemic crisis
AU1868195A (en)	1995-08-15	Cell signaling inhibitors
AU1372097A (en)	1997-07-28	Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation
AU561449B2 (en)	1987-05-07	Pharmaceutical 3-aryl-7-chloro-9-oxo-3,4-dihyroacridines
AU688161B2 (en)	1998-03-05	Indicator
AU5869790A (en)	1991-01-10	Fungicidal guanidines
AU1968688A (en)	1989-01-30	Orally active antiandrogens
AU1090800A (en)	2000-03-27	Linker-assisted immunoassay for glyphosate
HUP0001879A3 (en)	2001-03-28	Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids
AU3986595A (en)	1996-07-19	Production of water-less lithographic plates
AU575536B2 (en)	1988-08-04	Lampholder
AU3922595A (en)	1996-06-26	Indicator
AU3184295A (en)	1996-03-07	Water-less lithographic plates
HK1008451B (en)	1999-05-07	Lampholder
HK1008451A1 (en)	1999-05-07	Lampholder
AU557483B2 (en)	1986-12-24	Fluid discharge silencer